SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Mps1-IN-3

Item No. 41029

CAS Registry No.: 1609584-72-6
Formal Name: 1-[3-methoxy-4-[[6-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-9H-purin-2-yl]amino]phenyl]-4-piperidinol
Synonyms: Monopolar Spindle1-IN-3, Monopolar Spindle 1 Inhibitor 3, Mps1 Inhibitor 3
MF: $C_{26}H_{31}N_7O_4S$
FW: 537.6
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mps1-IN-3 is supplied as a solid. A stock solution may be made by dissolving the Mps1-IN-3 in the solvent of choice, which should be purged with an inert gas. Mps1-IN-3 is slightly soluble (0.1-1 mg/ml) in DMSO.

Description

Mps1-IN-3 is an inhibitor of monopolar spindle 1 (Mps1; IC_{50} = 50 nM).[1] It inhibits the proliferation of U251 glioblastoma cells (IC_{50} = ~5 µM). Mps1-IN-3 (2 µM) prevents checkpoint-mediated mitotic arrest induced by nocodazole (Item No. 13857) in U2OS osteosarcoma cells and, when used at a concentration of 5 µM in combination with the antimitotic agents vincristine (Item No. 11764) or paclitaxel (Item No. 10461), induces nuclear aberrancies and chromosome missegregation defects in U251-FM-H2B-GFP cells, which express firefly luciferase, mCherry, and a histone H2B-GFP fusion reporter. It sensitizes U251-FM cells to vincristine and increases survival in an orthotopic mouse model of glioblastoma when administered at a dose of 2 mg/kg.

Reference

1. Tannous, B.A., Kerami, M., Van der Stoop, P.M., *et al.* Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. *J. Natl. Cancer Inst.* **105(17)**, 1322-1331 (2013).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM